WNK2 and melanoma: In principle, melanoma can be targeted from complementary angles, including immune-checkpoint inhibitors (IMMUNOi) and/or targeted therapy with inhibitors of specific signaling pathways such as the mitogen-activated protein kinase inhibitors (MAPKi), epigenetic inhibitors (EPIi), or metabolic inhibitors (METABi) (Fig. 1c).